{"success":true,"data":{"pressRelease":{"id":"134547","rtpr_id":"nGNX1y5Wr6","ticker":"EYPT","exchange":"NASDAQ","all_tickers":["EYPT"],"title":"EYPT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving EyePoint Pharmaceuticals","author":"Globe Newswire","published_at":"2026-09-03T00:00:00.088Z","article_body":"NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney\nLLP\n(https://www.globenewswire.com/Tracker?data=w2oObZdX8Yg7wtnk_aoa8bedKg_uC4xUCiRzIN6hWN_FrmBCYOYJ7fucVFLkiPLDp1vbgsKogqTB7ctIM4mQuKZVQR3Ux3f3xPFCJcs5f-I=)\ncontinues its investigation on behalf of EyePoint Pharmaceuticals\n(“EyePoint” or the “Company”) (NASDAQ: EYPT) investors concerning the\nCompany’s and/or members of its senior management’s possible violation of\nthe federal securities laws and other unlawful business practices.\n\n[CONTACT THE FIRM IF YOU SUFFERED A LOSS\n(https://www.globenewswire.com/Tracker?data=5Vdn4JUdrcAbjEOwx5o8wrZ7F_zEPoQgcBmqAiamz2wPQMv0MTmLODNdmoaIS8YP7EdorFwNZcQCbDFgBwuuVUK0g2wPZGXLY6xT8eNJqC_lZpDI3E1z6hgoiXaVcCNqYYDK9Vq0x-Wv1GpBHWSZRmNLahkE5qSINMtMn1_xbvOiDib2o_0EJ2RpSAWi0XD6)]\n\nWhat Happened?\n\nOn August 14, 2026, EyePoint released topline results in its Phase 3 LUGANO\nwet AMD trial for DURAVYU, revealing that DURAVYU missed the prespecified\nprimary endpoint—change in best-corrected visual acuity versus on-label\naflibercept. Previously, on March 25, 2026, President and CEO Jay S. Duker had\nstated they were “highly confident in the results of these trials [including\nPhase 3 LUGANO] at this point for a lot of reasons.” On June 9, he\nreiterated that they “remain quite confident and quite optimistic in the\nresults and we think we can make a difference for patients.” On this news,\nthe Company’s stock price declined $9.88, or 67%, to close at $4.87 on\nAugust 17, 2026.\n\nWhat Should I Do?\n\nAt this stage, no lawsuit has been filed. The investigation is ongoing to\ndetermine whether claims may be brought under federal securities laws.\n\nIf you purchased or otherwise acquired EyePoint securities, have information,\nor would like to learn more about this investigation, please contact Lauren\nMolinaro\n(https://www.globenewswire.com/Tracker?data=55KnqDKE1hX6o28_tGBaAsNCC7SY1cpZ1X4i1IKDKbihA9qRghf1_IVtGFoBCns95W2pfIrFil4cU8DEho9sC6BnTI1GomW2q9epmdvfSgMifEdoC4J9Q6cd3sfLBu5s)\nof Kirby McInerney LLP\n(https://www.globenewswire.com/Tracker?data=w2oObZdX8Yg7wtnk_aoa8Z139aTgca-RNO7lQQ48_5vb-BBR9U4TVQFGm8LDMLJQZIjKx6BnYs_r1EMAeqfsN8FfQT6Z0Hfcy8DPm46vqhk=)\nby email at investigations@kmllp.com, or fill out the contact form below, to\ndiscuss your rights or interests with respect to these matters at no cost.\n\n[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]\n(https://www.globenewswire.com/Tracker?data=YT__2oq7XpdeiluNpQuwDTHZBSLv3hqkzf4dVV6T_Bmc-regwIXy6OXlbtStQODRUb5i4CRmsX4Z8uvxQ4dVaa5WprQyV4Ond5gP3NrXExTnidqJPHKWjHkXxb9GcCnFP4W1JOmwIG6DFpNF8xlNaQ==)\n\nKirby McInerney LLP\n(https://www.globenewswire.com/Tracker?data=w2oObZdX8Yg7wtnk_aoa8XAlBya7zRPhs9Jw0O_ipyhTXrrP4jgqg4pKPZGy7QNGmcikChKcsBRO_UHeSgScA4MJUsMVqTUUIM-GvHeUIfw=)\nis a New York-based plaintiffs’ law firm concentrating in securities,\nantitrust, whistleblower, and consumer litigation. The firm’s efforts on\nbehalf of shareholders in securities litigation have resulted in recoveries\ntotaling billions of dollars. Additional information about the firm can be\nfound at Kirby McInerney LLP’s website\n(https://www.globenewswire.com/Tracker?data=tN8CahN4WNOUnXQdQRgkNyhaDdhFn558qCBQBUEU-RJJJVo2MevswtU5TWNAQzgtX4OM-SBnTAQXps3rXm8wlA==).\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and ethical rules.\n\nContacts\nKirby McInerney LLP        \nLauren Molinaro, Esq.\n212-699-1171\nhttps://www.kmllp.com\nhttps://securitiesleadplaintiff.com/\ninvestigations@kmllp.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/192da1d1-643f-4eee-b850-dde5b9f2b00f)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX1y5Wr6","title":"EYPT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving EyePoint Pharmaceuticals","author":"Globe Newswire","ticker":"EYPT","created":"2026-09-03T00:00:00.088Z","tickers":["EYPT"],"exchange":"NASDAQ","article_body":"NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney\nLLP\n(https://www.globenewswire.com/Tracker?data=w2oObZdX8Yg7wtnk_aoa8bedKg_uC4xUCiRzIN6hWN_FrmBCYOYJ7fucVFLkiPLDp1vbgsKogqTB7ctIM4mQuKZVQR3Ux3f3xPFCJcs5f-I=)\ncontinues its investigation on behalf of EyePoint Pharmaceuticals\n(“EyePoint” or the “Company”) (NASDAQ: EYPT) investors concerning the\nCompany’s and/or members of its senior management’s possible violation of\nthe federal securities laws and other unlawful business practices.\n\n[CONTACT THE FIRM IF YOU SUFFERED A LOSS\n(https://www.globenewswire.com/Tracker?data=5Vdn4JUdrcAbjEOwx5o8wrZ7F_zEPoQgcBmqAiamz2wPQMv0MTmLODNdmoaIS8YP7EdorFwNZcQCbDFgBwuuVUK0g2wPZGXLY6xT8eNJqC_lZpDI3E1z6hgoiXaVcCNqYYDK9Vq0x-Wv1GpBHWSZRmNLahkE5qSINMtMn1_xbvOiDib2o_0EJ2RpSAWi0XD6)]\n\nWhat Happened?\n\nOn August 14, 2026, EyePoint released topline results in its Phase 3 LUGANO\nwet AMD trial for DURAVYU, revealing that DURAVYU missed the prespecified\nprimary endpoint—change in best-corrected visual acuity versus on-label\naflibercept. Previously, on March 25, 2026, President and CEO Jay S. Duker had\nstated they were “highly confident in the results of these trials [including\nPhase 3 LUGANO] at this point for a lot of reasons.” On June 9, he\nreiterated that they “remain quite confident and quite optimistic in the\nresults and we think we can make a difference for patients.” On this news,\nthe Company’s stock price declined $9.88, or 67%, to close at $4.87 on\nAugust 17, 2026.\n\nWhat Should I Do?\n\nAt this stage, no lawsuit has been filed. The investigation is ongoing to\ndetermine whether claims may be brought under federal securities laws.\n\nIf you purchased or otherwise acquired EyePoint securities, have information,\nor would like to learn more about this investigation, please contact Lauren\nMolinaro\n(https://www.globenewswire.com/Tracker?data=55KnqDKE1hX6o28_tGBaAsNCC7SY1cpZ1X4i1IKDKbihA9qRghf1_IVtGFoBCns95W2pfIrFil4cU8DEho9sC6BnTI1GomW2q9epmdvfSgMifEdoC4J9Q6cd3sfLBu5s)\nof Kirby McInerney LLP\n(https://www.globenewswire.com/Tracker?data=w2oObZdX8Yg7wtnk_aoa8Z139aTgca-RNO7lQQ48_5vb-BBR9U4TVQFGm8LDMLJQZIjKx6BnYs_r1EMAeqfsN8FfQT6Z0Hfcy8DPm46vqhk=)\nby email at investigations@kmllp.com, or fill out the contact form below, to\ndiscuss your rights or interests with respect to these matters at no cost.\n\n[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]\n(https://www.globenewswire.com/Tracker?data=YT__2oq7XpdeiluNpQuwDTHZBSLv3hqkzf4dVV6T_Bmc-regwIXy6OXlbtStQODRUb5i4CRmsX4Z8uvxQ4dVaa5WprQyV4Ond5gP3NrXExTnidqJPHKWjHkXxb9GcCnFP4W1JOmwIG6DFpNF8xlNaQ==)\n\nKirby McInerney LLP\n(https://www.globenewswire.com/Tracker?data=w2oObZdX8Yg7wtnk_aoa8XAlBya7zRPhs9Jw0O_ipyhTXrrP4jgqg4pKPZGy7QNGmcikChKcsBRO_UHeSgScA4MJUsMVqTUUIM-GvHeUIfw=)\nis a New York-based plaintiffs’ law firm concentrating in securities,\nantitrust, whistleblower, and consumer litigation. The firm’s efforts on\nbehalf of shareholders in securities litigation have resulted in recoveries\ntotaling billions of dollars. Additional information about the firm can be\nfound at Kirby McInerney LLP’s website\n(https://www.globenewswire.com/Tracker?data=tN8CahN4WNOUnXQdQRgkNyhaDdhFn558qCBQBUEU-RJJJVo2MevswtU5TWNAQzgtX4OM-SBnTAQXps3rXm8wlA==).\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and ethical rules.\n\nContacts\nKirby McInerney LLP        \nLauren Molinaro, Esq.\n212-699-1171\nhttps://www.kmllp.com\nhttps://securitiesleadplaintiff.com/\ninvestigations@kmllp.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/192da1d1-643f-4eee-b850-dde5b9f2b00f)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-03T00:00:00.134477092Z","server_sent_at_ms":1788393600134},"received_at":"2026-09-03T00:00:00.195Z","source_url":null},"analysis":{"id":"123438","press_release_id":"134547","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Phase 3 LUGANO trial for DURAVYU missed its prespecified primary endpoint vs. aflibercept","shares collapsed 67% ($9.88 to $4.87) on the August 17, 2026 trial readout","CEO publicly expressed confidence in trial results before the miss, now cited as basis for potential securities-law claims"],"eventType":"legal_litigation","narrative":"Kirby McInerney LLP is investigating potential federal securities-law claims on behalf of EyePoint Pharmaceuticals (NASDAQ: EYPT) investors concerning possible violations by the company and/or its senior management; at this stage, no lawsuit has been filed.\n\nThe probe follows EyePoint's August 14, 2026 topline disclosure that DURAVYU missed the prespecified primary endpoint in the Phase 3 LUGANO wet AMD trial versus on-label aflibercept, after which the stock declined $9.88, or 67%, to close at $4.87 on August 17, 2026.\n\nThe release recites earlier public statements of confidence in the trial results from President and CEO Jay S. Duker as the alleged basis for claims; it is law-firm solicitation rather than issuer disclosure, so treat as low-signal noise.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation riding the already-priced-in DURAVYU Phase 3 failure -- suppress."},"keyFigures":{"customDimensions":{"stock_decline_pct":"67%","stock_decline_usd":9.88,"close_price_aug_17_2026":4.87}},"quotedText":"highly confident in the results of these trials [including Phase 3 LUGANO] at this point for a lot of reasons","namedEntities":{"people":[{"name":"Jay S. Duker","role":"President and CEO of EyePoint Pharmaceuticals"},{"name":"Lauren Molinaro","role":"Esq., contact at Kirby McInerney LLP"}],"products":["DURAVYU","aflibercept","LUGANO"],"companies":[{"name":"Kirby McInerney LLP","relationship":"plaintiff law firm"},{"name":"EyePoint Pharmaceuticals","ticker":"EYPT","relationship":"investigation target / issuer"}],"dollarAmounts":[{"amount":"$9.88","context":"stock price decline on August 17, 2026"},{"amount":"$4.87","context":"closing price on August 17, 2026"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation issued by Kirby McInerney LLP seeking EyePoint investors who suffered losses; no lawsuit has been filed and no new issuer disclosure or court action occurred. The underlying Phase 3 miss is background recitation, not new information from the company."},"tickerRelevance":{"others":[],"primary":"EYPT"},"globalImportance":18,"audienceRelevance":14,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap biotech","eventGravity":"law-firm-investigation-solicitation","lawsuitFiled":false,"issuerAuthored":false,"retailFavoriteBoost":"moderate -- EYPT has retail following after 67% drawdown","underlyingEventGravity":"phase-3-trial-miss-already-public"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Kirby McInerney LLP is investigating potential federal securities-law claims on behalf of EyePoint Pharmaceuticals (NASDAQ: EYPT) investors concerning possible violations by the company and/or its senior management; at this stage, no lawsuit has been filed.\n\nThe probe follows EyePoint's August 14, 2026 topline disclosure that DURAVYU missed the prespecified primary endpoint in the Phase 3 LUGANO wet AMD trial versus on-label aflibercept, after which the stock declined $9.88, or 67%, to close at $4.87 on August 17, 2026.\n\nThe release recites earlier public statements of confidence in the trial results from President and CEO Jay S. Duker as the alleged basis for claims; it is law-firm solicitation rather than issuer disclosure, so treat as low-signal noise.","key_figures":{"customDimensions":{"stock_decline_pct":"67%","stock_decline_usd":9.88,"close_price_aug_17_2026":4.87}},"named_entities":{"people":[{"name":"Jay S. Duker","role":"President and CEO of EyePoint Pharmaceuticals"},{"name":"Lauren Molinaro","role":"Esq., contact at Kirby McInerney LLP"}],"products":["DURAVYU","aflibercept","LUGANO"],"companies":[{"name":"Kirby McInerney LLP","relationship":"plaintiff law firm"},{"name":"EyePoint Pharmaceuticals","ticker":"EYPT","relationship":"investigation target / issuer"}],"dollarAmounts":[{"amount":"$9.88","context":"stock price decline on August 17, 2026"},{"amount":"$4.87","context":"closing price on August 17, 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-03T00:01:00.015Z","global_importance":18,"audience_relevance":14,"importance_components":{"tickerTier":"small-cap biotech","eventGravity":"law-firm-investigation-solicitation","lawsuitFiled":false,"issuerAuthored":false,"retailFavoriteBoost":"moderate -- EYPT has retail following after 67% drawdown","underlyingEventGravity":"phase-3-trial-miss-already-public"}},"durationMs":59809,"modelName":"glm-4.7"}}